BerGenBio ASA (BGBIO):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】BerGenBio ASA (BGBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8109)・商品コード:DATA904C8109
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:47
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
BerGenBio ASA (BerGenBio) is a clinical-stage biopharmaceutical company that develops drugs to treat multiple aggressive cancers. The company develops epithelial-mesenchymal transition inhibitors for acquired cancer drug-resistance and metastasis. Its BGB324 is an AXL kinase inhibitor which finds application in the treatment of drug-resistant chronic myeloid leukemia. BerGenBio’s cellselect is a drug discovery and validation technology that identifies and validates novel drug targets and biomarkers. The company’s cellselect imaging allows cell sorting, selection, and in-vivo disease imaging. Its cellselect modeling and regulated translational tools are used for disease and treatment in-vivo modeling. BerGenBio is headquartered in Bergen, Norway.

BerGenBio ASA (BGBIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BerGenBio ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
BerGenBio ASA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
BerGenBio Raises US$6.4 Million In Venture Financing 11
BerGenBio Secures US$8.8 Million In Series A Financing 13
Partnerships 14
BerGenBio Enters into Agreement with Merck 14
Licensing Agreements 15
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 15
Equity Offering 16
BerGenBio to Raise USD24 Million in Private Placement of Shares 16
BerGenBio Raises USD47 Million in IPO 17
BerGenBio Raises USD25 Million in Private Placement of Shares 18
BerGenBio Raises USD12 Million in Private Placement of Shares 19
BerGenBio Completes Private Placement Of Common Stock For US$11.9 Million 20
BerGenBio ASA – Key Competitors 21
BerGenBio ASA – Key Employees 22
BerGenBio ASA – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
May 15, 2018: BerGenBio: Results for the First Quarter 2018 24
Aug 18, 2017: BerGenBio: Results for the Second Quarter and Half year 2017 25
May 23, 2017: BerGenBio: Results for the First Quarter 2017 26
Product News 28
12/14/2017: BerGenBio to present recent highlights from its clinical trials with selective AXL inhibitor BGB324 at DNB’s 8th Annual Nordic Healthcare Conference 28
12/11/2017: BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting 29
11/17/2017: BerGenBio: Results for the Third Quarter 2017 30
11/01/2017: Clinical Study with BGB324, BerGenBios Selective First-in-Class AXL Inhibitor, Featured at the 2017 American Society of Hematology Annual Meeting 31
10/12/2017: Clinical Study with BGB324, BerGenBios Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma 32
06/06/2017: BerGenBio’s selective first-in-class Axl inhibitor, BGB324, Featured in a Poster Presentation at ASCO Annual Meeting 2017 33
01/09/2017: BerGenBio To Present At 9th Annual Biotech Showcase 2017 34
Clinical Trials 35
Jan 29, 2018: BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentinib (BGB324) supports its potential as cornerstone of cancer therapy 35
Jan 09, 2018: BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC 37
Jan 08, 2018: BerGenBio to present at Biotech Showcase 2018 38
Nov 14, 2017: BerGenBio Presents BGB324 and KEYTRUDA (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposium 39
Oct 19, 2017: BerGenBio Announces Start of Phase II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer 40
Sep 28, 2017: BGB324, BerGenBio’s Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer 41
Jul 26, 2017: BerGenBio to Present its First-In-Class, Selective AXL Inhibitor BGB324 at Precision: Lung Cancer – World R&D Summit in Boston 42
Jun 26, 2017: BerGenBio Awarded NOK 24m from Innovasjon Norge to Support the Clinical Development of BGB324 in Combination with KEYTRUDA for Advanced Lung Cancer 43
May 19, 2017: Abstract showing activity in MDS of BerGenBio’s first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017 44
Other Significant Developments 45
Aug 21, 2018: BerGenBio: Results for the Second Quarter and First Half 2018 45
Feb 13, 2018: BerGenBio: Results for the Fourth Quarter and Full Year 2017 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
BerGenBio ASA, Pharmaceuticals & Healthcare, Key Facts 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BerGenBio ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BerGenBio ASA, Deals By Therapy Area, 2012 to YTD 2018 9
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
BerGenBio Raises US$6.4 Million In Venture Financing 11
BerGenBio Secures US$8.8 Million In Series A Financing 13
BerGenBio Enters into Agreement with Merck 14
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 15
BerGenBio to Raise USD24 Million in Private Placement of Shares 16
BerGenBio Raises USD47 Million in IPO 17
BerGenBio Raises USD25 Million in Private Placement of Shares 18
BerGenBio Raises USD12 Million in Private Placement of Shares 19
BerGenBio Completes Private Placement Of Common Stock For US$11.9 Million 20
BerGenBio ASA, Key Competitors 21
BerGenBio ASA, Key Employees 22

List of Figures
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[BerGenBio ASA (BGBIO):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8109)販売に関する免責事項を必ずご確認ください。
★調査レポート[BerGenBio ASA (BGBIO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆